Evaluation of airway and circulating inflammatory biomarkers for cystic fibrosis drug development

Neutrophil-dominated airway inflammation is a hallmark feature of cystic fibrosis (CF) lung disease, playing a key role in its pathogenesis and progression [1]. Consequently, a major emphasis has been placed on evaluating drugs that target inflammation. Corticosteroids and high-dose ibuprofen, two of the first anti-inflammatory drugs studied in CF, both demonstrated clinical benefit [2-4], but side effects and other considerations have limited their use [5-7]. However, evidence that these anti-inflammatory agents can slow the progression of CF lung disease, suggests that strategies to modulate lung inflammation can be beneficial.

Source: Journal of Cystic Fibrosis - June 30, 2020 Category: Respiratory Medicine Authors: Raksha Jain, Arthur Baines, Umer Khan, Brandie D. Wagner, Scott D. Sagel Source Type: research